New PET scan shows promise for detecting rare tumors
NCT ID NCT06240741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new imaging method called [68Ga]Ga-DOTA-TATE PET/CT to see how well it finds neuroendocrine tumors compared to standard scans. It included 71 adults in Japan, both with and without the disease. The goal was to prove the new scan works well for diagnosis in Japan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Kashiwa, Chiba, 277 8577, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 060 8648, Japan
-
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 920 8641, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa-ku, 236-0004, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
Fukuoka, 8128582, Japan
-
Novartis Investigative Site
Fukuoka, 813-0017, Japan
-
Novartis Investigative Site
Kyoto, 6068507, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug shows promise for rare gut and lung tumors
- New imaging trial peers inside tumors to track experimental Drug's path
- Experimental combo aims to boost immune attack on tough lung cancers
- New drug combo targets rare, aggressive cancer in early trial
- New drug aims to shrink Hard-to-Treat lung cancers
- New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors